Nova Mentis Life Science Corp. (NMLSF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.2 Million CAD | -2.68% |
| 2022 | -1.17 Million CAD | 62.06% |
| 2021 | -3.08 Million CAD | -115.69% |
| 2020 | 19.66 Million CAD | 1857.1% |
| 2019 | -1.11 Million CAD | 69.42% |
| 2018 | -3.66 Million CAD | -111.14% |
| 2017 | -1.73 Million CAD | 11.61% |
| 2016 | -1.96 Million CAD | -178.41% |
| 2015 | -704.54 Thousand CAD | -43.44% |
| 2014 | -491.18 Thousand CAD | -160.07% |
| 2013 | -188.86 Thousand CAD | 71.37% |
| 2012 | -659.68 Thousand CAD | 33.16% |
| 2011 | -986.92 Thousand CAD | -41.25% |
| 2010 | -698.69 Thousand CAD | 62.39% |
| 2009 | -1.85 Million CAD | -146.29% |
| 2008 | -754.31 Thousand CAD | -22.81% |
| 2007 | -614.19 Thousand CAD | -503.79% |
| 2006 | -101.72 Thousand CAD | -63.44% |
| 2005 | -62.24 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -145.56 Thousand CAD | 30.91% |
| 2024 Q2 | -90.75 Thousand CAD | 37.65% |
| 2023 Q4 | -210.67 Thousand CAD | -10.48% |
| 2023 Q3 | -190.69 Thousand CAD | 37.02% |
| 2023 FY | -1.23 Million CAD | -5.23% |
| 2023 Q1 | -528 Thousand CAD | -256.22% |
| 2023 Q2 | -302.79 Thousand CAD | 42.65% |
| 2022 Q2 | -393.78 Thousand CAD | 40.53% |
| 2022 FY | -1.17 Million CAD | 62.06% |
| 2022 Q4 | 337.98 Thousand CAD | 174.62% |
| 2022 Q3 | -452.97 Thousand CAD | -15.03% |
| 2022 Q1 | -662.11 Thousand CAD | -13.79% |
| 2021 Q2 | -424.97 Thousand CAD | 31.17% |
| 2021 Q1 | -617.44 Thousand CAD | -104.37% |
| 2021 Q4 | -581.88 Thousand CAD | 60.19% |
| 2021 FY | -3.08 Million CAD | -115.69% |
| 2021 Q3 | -1.46 Million CAD | -243.93% |
| 2020 Q1 | -120.56 Thousand CAD | -756.1% |
| 2020 Q4 | 14.12 Million CAD | 3095.76% |
| 2020 Q2 | 6.13 Million CAD | 5191.29% |
| 2020 Q3 | -471.44 Thousand CAD | -107.68% |
| 2020 FY | 19.66 Million CAD | 1857.1% |
| 2019 Q3 | -469.32 Thousand CAD | -66.71% |
| 2019 Q4 | -14.08 Thousand CAD | 97.0% |
| 2019 Q2 | -281.52 Thousand CAD | 20.58% |
| 2019 FY | -1.11 Million CAD | 69.42% |
| 2019 Q1 | -354.49 Thousand CAD | 33.56% |
| 2018 Q3 | -704.58 Thousand CAD | -143.41% |
| 2018 FY | -3.66 Million CAD | -111.14% |
| 2018 Q4 | -533.58 Thousand CAD | 24.27% |
| 2018 Q1 | -2.11 Million CAD | -165.43% |
| 2018 Q2 | -289.46 Thousand CAD | 86.31% |
| 2017 FY | -1.73 Million CAD | 11.61% |
| 2017 Q4 | -796.62 Thousand CAD | -137.03% |
| 2017 Q3 | -336.08 Thousand CAD | -0.39% |
| 2017 Q2 | -334.78 Thousand CAD | -25.77% |
| 2017 Q1 | -266.18 Thousand CAD | 83.28% |
| 2016 Q4 | -1.59 Million CAD | -720.22% |
| 2016 Q3 | -194.05 Thousand CAD | -114.01% |
| 2016 Q2 | -90.67 Thousand CAD | -6.43% |
| 2016 Q1 | -85.19 Thousand CAD | 64.39% |
| 2016 FY | -1.96 Million CAD | -178.41% |
| 2015 Q2 | -115.74 Thousand CAD | 31.56% |
| 2015 FY | -704.54 Thousand CAD | -43.44% |
| 2015 Q4 | -239.25 Thousand CAD | -32.6% |
| 2015 Q1 | -169.11 Thousand CAD | -12.9% |
| 2015 Q3 | -180.43 Thousand CAD | -55.89% |
| 2014 Q1 | -72.51 Thousand CAD | -1223.33% |
| 2014 Q2 | -137.37 Thousand CAD | -89.46% |
| 2014 FY | -491.18 Thousand CAD | -160.07% |
| 2014 Q4 | -149.78 Thousand CAD | -4.03% |
| 2014 Q3 | -143.99 Thousand CAD | -4.82% |
| 2013 Q4 | 6455.00 CAD | 107.11% |
| 2013 Q3 | -90.82 Thousand CAD | -95.57% |
| 2013 Q2 | -46.44 Thousand CAD | 20.01% |
| 2013 Q1 | -58.05 Thousand CAD | 60.93% |
| 2013 FY | -188.86 Thousand CAD | 71.37% |
| 2012 FY | -659.68 Thousand CAD | 33.16% |
| 2012 Q4 | -148.6 Thousand CAD | 29.66% |
| 2012 Q3 | -211.27 Thousand CAD | -63.82% |
| 2012 Q2 | -128.96 Thousand CAD | 24.59% |
| 2012 Q1 | -171.01 Thousand CAD | 47.28% |
| 2011 Q2 | -331.79 Thousand CAD | -63.46% |
| 2011 FY | -986.92 Thousand CAD | -41.25% |
| 2011 Q3 | -213.95 Thousand CAD | 35.52% |
| 2011 Q1 | -202.97 Thousand CAD | -40.31% |
| 2011 Q4 | -324.4 Thousand CAD | -51.62% |
| 2010 FY | -698.69 Thousand CAD | 62.39% |
| 2010 Q3 | -149.64 Thousand CAD | 9.78% |
| 2010 Q2 | -165.87 Thousand CAD | 30.46% |
| 2010 Q4 | -144.65 Thousand CAD | 3.33% |
| 2010 Q1 | -238.51 Thousand CAD | 40.1% |
| 2009 Q4 | -398.18 Thousand CAD | 13.42% |
| 2009 Q1 | -606.39 Thousand CAD | -215.76% |
| 2009 FY | -1.85 Million CAD | -146.29% |
| 2009 Q2 | -376.45 Thousand CAD | 37.92% |
| 2009 Q3 | -459.9 Thousand CAD | -22.17% |
| 2008 Q3 | -322.67 Thousand CAD | -71.55% |
| 2008 FY | -754.31 Thousand CAD | -22.81% |
| 2008 Q1 | -51.5 Thousand CAD | 83.48% |
| 2008 Q4 | -192.04 Thousand CAD | 40.48% |
| 2008 Q2 | -188.09 Thousand CAD | -265.2% |
| 2007 Q2 | -94.71 Thousand CAD | 1.89% |
| 2007 Q3 | -101.95 Thousand CAD | -7.64% |
| 2007 Q4 | -311.79 Thousand CAD | -205.82% |
| 2007 FY | -614.19 Thousand CAD | -503.79% |
| 2007 Q1 | -96.54 Thousand CAD | -78.92% |
| 2006 FY | -101.72 Thousand CAD | -63.44% |
| 2006 Q4 | -53.95 Thousand CAD | -216.39% |
| 2006 Q3 | -17.05 Thousand CAD | -13.23% |
| 2006 Q2 | -15.06 Thousand CAD | -10276.35% |
| 2006 Q1 | 148.00 CAD | 0.0% |
| 2005 FY | -62.24 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.325% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 124.463% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.414% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 93.263% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.469% |
| Mesoblast Limited | -84.14 Million USD | 98.571% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 21.728% |
| Genus plc | 6.4 Million USD | 118.786% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 112.341% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -29.088% |
| Marizyme, Inc. | -34.08 Million USD | 96.473% |
| ContraFect Corporation | -56.88 Million USD | 97.887% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 85.601% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 73.603% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 14.243% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 57.822% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 56.293% |
| MultiCell Technologies, Inc. | -722.81 USD | -166236.797% |
| Accustem Sciences Inc. | -3.74 Million USD | 67.908% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 97.962% |
| EV Biologics, Inc. | -483.06 Thousand USD | -148.891% |
| Q BioMed Inc. | -3.44 Million USD | 65.106% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 133.963% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -208.622% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 54.242% |
| Biomind Labs Inc. | -1 Million USD | -19.086% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 75.36% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 81.915% |
| Skye Bioscience, Inc. | -13.67 Million USD | 91.206% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 39.476% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -3914.086% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 76.166% |
| IMV Inc. | -38.67 Million USD | 96.891% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 92.424% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 37.789% |
| GB Sciences, Inc. | -1.42 Million USD | 15.361% |
| Alpha Cognition Inc. | -9.7 Million USD | 87.612% |
| HST Global, Inc. | -140.9 Thousand USD | -753.257% |
| CSL Limited | 3.7 Billion USD | 100.032% |
| Halberd Corporation | -75.05 Thousand USD | -1501.997% |
| Enzolytics Inc. | -2.14 Million USD | 44.048% |
| Resverlogix Corp. | -12.74 Million USD | 90.569% |
| Affymax, Inc. | -15.04 Million USD | 92.009% |
| SYBLEU INC | -149.18 Thousand USD | -705.938% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 62.052% |
| argenx SE | -425.04 Million USD | 99.717% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 97.834% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -15.163% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 23.874% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 64.69% |
| AVAX Technologies, Inc. | 6.69 Million USD | 117.964% |
| Zenith Capital Corp. | -8.94 Million USD | 86.556% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.711% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -6801.435% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 51.033% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -601.01% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 97.813% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 58.559% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -22.178% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 35.512% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 4.276% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 40.028% |
| BioStem Technologies, Inc. | -7.77 Million USD | 84.544% |
| ONE Bio Corp. | 13.68 Million USD | 108.788% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -562.478% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 9.969% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -6.88% |
| Agentix Corp. | -1.37 Million USD | 12.353% |
| LadRx Corporation | -3.82 Million USD | 68.556% |
| Cell Source, Inc. | -4.32 Million USD | 72.203% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -189.377% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -75.02% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -75.02% |
| NovAccess Global Inc. | -2.46 Million USD | 51.26% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 58.818% |
| Itoco Inc. | -919.14 Thousand USD | -30.807% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 71.633% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -7.444% |
| Kadimastem Ltd | -3.04 Million USD | 60.454% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -359.373% |
| CytoDyn Inc. | -18.05 Million USD | 93.342% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -4676.714% |
| Mobile Lads Corp. | -554.55 Thousand USD | -116.806% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -446.306% |
| Qrons Inc. | -643.67 Thousand USD | -86.786% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -112.901% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | 46.082% |
| Rebus Holdings, Inc. | -664 Thousand USD | -81.069% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 33.806% |
| International Stem Cell Corporation | -663 Thousand USD | -81.342% |
| Bioxytran, Inc. | -3.82 Million USD | 68.527% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2184.003% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -5811.008% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 96.685% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 25.692% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -63.392% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 61.353% |
| Neutra Corp. | -229.48 Thousand USD | -423.91% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 93.145% |
| PureTech Health plc | -146.19 Million USD | 99.178% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 94.406% |
| IXICO plc | -1.43 Million USD | 16.333% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 87.332% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.013% |
| CSL Limited | 3.81 Billion USD | 100.032% |
| Cellectis S.A. | -108.85 Million USD | 98.896% |